International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk0–0
- Intermediate Risk1–1
- High Risk2–3
The International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E) calculator is designed for bedside assessing prognosis of asymptomatic early-stage chronic lymphocytic leukemia (CLL) to predict time to first treatment (TTFT) in clinical practice. The resulting score directly guides clinician decision-making regarding initiating targeted anticoagulation therapy.
Clinical Guidelines & Evidence
Assesses prognosis of asymptomatic early-stage chronic lymphocytic leukemia (CLL) to predict time to first treatment (TTFT). The IPS-E was developed using individual patient data from 11 international cohorts (n=4933) and uses three independent prognostic factors to stratify patients into low, intermediate, and high-risk categories. This scoring system specifically addresses the clinical need for prognostic stratification in early-stage asymptomatic CLL patients who do not require immediate treatment according to iwCLL criteria. The IPS-E demonstrates excellent discrimination with C-index values of 0.74 in training and 0.70 in validation cohorts, making it a valuable tool for clinical management and early intervention clinical trial design. It enables clinicians to identify patients who may benefit from closer monitoring or consideration for clinical trials.
Clinical Indication
The International Prognostic Score for Asymptomatic Early-stage CLL (IPS-E) is indicated for bedside clinical practice to support Assesses prognosis of asymptomatic early-stage chronic lymphocytic leukemia (CLL) to predict time to first treatment (TTFT). The IPS-E was developed using individual patient data from 11 international cohorts (n=4933) and uses three independent prognostic factors to stratify patients into low, intermediate, and high-risk categories. This scoring system specifically addresses the clinical need for prognostic stratification in early-stage asymptomatic CLL patients who do not require immediate treatment according to iwCLL criteria. The IPS-E demonstrates excellent discrimination with C-index values of 0.74 in training and 0.70 in validation cohorts, making it a valuable tool for clinical management and early intervention clinical trial design. It enables clinicians to identify patients who may benefit from closer monitoring or consideration for clinical trials.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.
Limitations & Contraindications
Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.
Clinical Pearls & Action Plan
Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies. Guideline pearl: Primary endpoint is time to first treatment (TTFT) according to iwCLL criteria.
IPS-E Score = Unmutated IGHV (1) + Lymphocyte count >15×10⁹/L (1) + Palpable lymph nodes (1). Score ranges 0-3: Low risk (0), Intermediate risk (1), High risk (2-3)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| ighv_status | string | Yes | Immunoglobulin heavy variable gene (IGHV) mutational status |
| lymphocyte_count | string | Yes | Absolute lymphocyte count at diagnosis(×10⁹/L) |
| palpable_lymph_nodes | string | Yes | Presence of palpable lymph nodes on physical examination |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Low Risk | Score 0 points |
| 1–1 | Intermediate Risk | Score 1 point |
| 2–3 | High Risk | Score 2-3 points |
Evidence-Based References (EBM)
- Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020 May 21;135(21):1859-1869. doi: 10.1182/blood.2019003453.DOI: 10.1182/blood.2019003453
- Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398.DOI: 10.1182/blood-2017-09-806398
- Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219-34. doi: 10.1182/blood.V46.2.219.219.DOI: 10.1182/blood.V46.2.219.219
Related calculators
- Binet Staging System for Chronic Lymphocytic Leukemia (CLL)
- International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI)
- BALL Score for Relapsed/Refractory CLL
- EUTOS Score for Chronic Myelogenous Leukemia (CML)
- International Prognostic Index for Diffuse Large B-cell Lymphoma (IPI and R-IPI)